✻ Science
Novel CAAR & ISER
The CAR-T developed by Caarlogic Biomed can simultaneously carry two types of CARs: one is a traditional single-chain CAR, and the other is an immune synapse enhancing receptor (ISER). The traditional CAR moiety can be viewed as a precise arrow targeting a specific single antigen epitope. For the ISER, we genetically engineer an adapter protein that can form a complex with the ISER, helping to generate a stable cytotoxic immune synapse. The ISER can also target antigens that are often expressed on cancer cells or other immunosuppressive cells in the tumor microenvironment. Therefore, chimeric arrow adapter receptors (CAAR) can reduce the risk of cancer cell evasion and form a robust cytolytic immune synapse, especially for solid tumors.
Additionally, Caarlogic Biomed uses camelid antibodies to construct the tumor antigen binding site of the CAR, which brings significant advantages, including pH and thermal stability, ease of production, and a lower risk of human anti-drug antibodies.
Cell manufacturing
The T cell manufacturing process, a critical factor in CAR-T cell quality, has been significantly improved and shortened. Superior to traditional cytokines of IL-2 or IL-7 plus IL-15, Caarlogic Biomed has developed a new process that not only can efficiently increase the proportion of Tscm (stem cell memory T cell) in vitro but also equip CAR-T cells with excellent secondary antigen exposure response, proliferation capabilities, and substantial persistence, and all of which enhance therapeutic efficacy in vivo.
Besides lentivirus, Caarlogic Biomed also explores the non-viral approach using RNA. With a deep understanding of RNA, we are able to broaden its application in the near future.
T cell boosting
Post-infusional CAR-T cells become exhausted after repeated exposure to tumors. Caarlogic Biomed’s goal is to revive in vivo exhausted CAR-T cells using next-generation immunocytokines. This combined approach is expected to enhance CAR-T effectiveness and significantly improve patient treatment outcomes.
Pipeline
Caarlogic Biomed’s pipeline is driven by state-of-the-art technologies, focusing on conquering hematological and solid cancers, as well as autoimmune diseases. Our team is making efforts to address these critical medical needs through clinical trials.
Currently, Caarlogic Biomed does not provide any compassionate use programs to physicians or patients.
